Simple Summary The landscape of treatment of patients with melanoma brain metastases (MBM) is continually evolving. We report the real-world data on 531 internationally treated patients with MBM before and after 2017 and their prognosis and treatment outcomes before the introduction of combined immunotherapy. We aimed to analyze trends in survival probability and their relevance to the currently used prognostic index, melanoma mol-GPA, and to some presumed prognostic and predictive factors not included in mol-GPA, such as symptoms occurrence and use of steroids. We have observed significant improvement in the survival of patients with the poorest mol-GPA prognosis. In our prognostic model, the presence of symptoms associated with brain metastases predicted a worse response to immune checkpoint inhibitors; however, symptoms without steroid use did not have prognostic significance. The prognosis of patients with MBM has been improving over the years due to the introduction of modern local and systemic treatment options across all mol-GPA prognostic groups. Stage IV melanoma patients develop melanoma brain metastases (MBM) in 50% of cases. Their prognosis is improving, and its understanding outside the context of clinical trials is relevant. We have retrospectively analyzed the clinical data, course of treatment, and outcomes of 531 subsequent stage IV melanoma patients with BM treated in five reference Italian and Polish melanoma centers between 2014 and 2021. Patients with MBM after 2017 had a better prognosis, with a significantly improved median of overall survival (OS) after 2017 in the worst mol-GPA prognostic groups (mol-GPA <= 2): a median OS >6 months and HR 0.76 vs. those treated before 2017 (CI: 0.60-0.97, p = 0.027). In our prognostic model, mol-GPA was highly predictive for survival, and symptoms without steroid use did not have prognostic significance. Local therapy significantly improved survival regardless of the year of diagnosis (treated before or after 2017), with median survival >12 months. Systemic therapy improved outcomes when it was combined with local therapy. Local surgery was associated with improved OS regardless of the timing related to treatment start (i.e., before or after 30 days from MBM diagnosis). Local and systemic treatment significantly prolong survival for the poorest mol-GPA prognosis. Use of modern treatment modalities is justified in all mol-GPA prognostic groups.

The Analysis of Trends in Survival for Patients with Melanoma Brain Metastases with Introduction of Novel Therapeutic Options before the Era of Combined Immunotherapy-Multicenter Italian-Polish Report

Tucci, Marco;
2022-01-01

Abstract

Simple Summary The landscape of treatment of patients with melanoma brain metastases (MBM) is continually evolving. We report the real-world data on 531 internationally treated patients with MBM before and after 2017 and their prognosis and treatment outcomes before the introduction of combined immunotherapy. We aimed to analyze trends in survival probability and their relevance to the currently used prognostic index, melanoma mol-GPA, and to some presumed prognostic and predictive factors not included in mol-GPA, such as symptoms occurrence and use of steroids. We have observed significant improvement in the survival of patients with the poorest mol-GPA prognosis. In our prognostic model, the presence of symptoms associated with brain metastases predicted a worse response to immune checkpoint inhibitors; however, symptoms without steroid use did not have prognostic significance. The prognosis of patients with MBM has been improving over the years due to the introduction of modern local and systemic treatment options across all mol-GPA prognostic groups. Stage IV melanoma patients develop melanoma brain metastases (MBM) in 50% of cases. Their prognosis is improving, and its understanding outside the context of clinical trials is relevant. We have retrospectively analyzed the clinical data, course of treatment, and outcomes of 531 subsequent stage IV melanoma patients with BM treated in five reference Italian and Polish melanoma centers between 2014 and 2021. Patients with MBM after 2017 had a better prognosis, with a significantly improved median of overall survival (OS) after 2017 in the worst mol-GPA prognostic groups (mol-GPA <= 2): a median OS >6 months and HR 0.76 vs. those treated before 2017 (CI: 0.60-0.97, p = 0.027). In our prognostic model, mol-GPA was highly predictive for survival, and symptoms without steroid use did not have prognostic significance. Local therapy significantly improved survival regardless of the year of diagnosis (treated before or after 2017), with median survival >12 months. Systemic therapy improved outcomes when it was combined with local therapy. Local surgery was associated with improved OS regardless of the timing related to treatment start (i.e., before or after 30 days from MBM diagnosis). Local and systemic treatment significantly prolong survival for the poorest mol-GPA prognosis. Use of modern treatment modalities is justified in all mol-GPA prognostic groups.
File in questo prodotto:
File Dimensione Formato  
cancers-14-05763.pdf

accesso aperto

Descrizione: Article
Tipologia: Documento in Versione Editoriale
Licenza: Creative commons
Dimensione 2.95 MB
Formato Adobe PDF
2.95 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11586/416372
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 5
social impact